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Abstract 27 
Over the last 15 years there has been a change in how we understand the impact of the 28 
interaction between the tumour and the host on cancer outcomes.  From the simplistic view 29 
that the make-up of tumours cells largely determines their aggressiveness to a more complex 30 
view that the interaction between the products of tumour and host cell signal transduction 31 
pathways is crucial in determining whether the tumour cell is eliminated or survives in the 32 
host. Of the host cells, those with an immune/inflammatory function are most well 33 
documented to inhibit or promote tumour cell proliferation and dissemination.   34 
It is only in the last few years that there has been greater recognition of the impact of 35 
intracellular, cellular and systemic immune/inflammatory phenotypes on patient outcomes 36 
independent of current tumour staging and that these phenotypes are useful in informing 37 
oncological research and practice.  In the present review we will examine the importance of 38 
inflammatory phenotypes at the intra-cellular, cellular and systemic levels on outcomes in 39 
patients with gastrointestinal cancer with focus on colorectal cancer. Based on these 40 
phenotypes we will examine and discuss the prospects for therapeutic intervention. 41 
  42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
  
 3 
Introduction 50 
 Over the past decade or so there has been a vast body of evidence focused on 51 
increasing our understanding of tumour-host interactions in colorectal cancer (CRC). The 52 
traditional view that CRC tumour progression stems from genetic alterations up-regulating 53 
pro-tumour genes and down-regulating tumour suppressive genes is out-dated. Instead, it has 54 
become clear that the interaction between the tumour and host immune cells plays a central 55 
role in determining disease progression (1, 2, 3).  56 
In the more recent view it is recognised that numerous genes become altered during the 57 
development of a tumour, however, it is also recognised that these tumour cells are 58 
maintained by the deregulation of specific signalling pathways (4). Therefore, these genetic 59 
events are part of a larger network that alters signal transduction pathways resulting in an 60 
increase in tumour cell proliferation and a decrease in tumour cell death.  In this network, 61 
these intracellular pathways within tumour cells do not function in isolation but regularly 62 
interact with stromal and immune cells.  Furthermore, this complex network of genetic events 63 
and signal transduction pathways result in growth factors and cytokines/chemokines that alter 64 
cellular behaviour at both local and systemic levels.  Of the host cells, those with an 65 
immune/inflammatory function are most well documented to inhibit or promote tumour cell 66 
proliferation and dissemination (5). Broadly these inflammatory responses have been 67 
considered as adaptive immune responses inhibiting tumour progression and innate immune 68 
responses promoting tumour progression (6).   69 
Unravelling the mechanisms of the immune systems involvement in CRC is a complex 70 
process due to its heterogeneous nature. There is a degree of plasticity to inflammation in 71 
cancer and components of the inflammatory infiltrate can exert both tumour-promoting and 72 
anti-tumour actions. Immunoediting describes the progression of a tumour from elimination, 73 
equilibrium to escape, whereby immune cells can eliminate, tolerate or be unable to kill the 74 
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cancer cells (7). The main cells involved in the elimination of the tumour are CD8+ T cells 75 
(CTLS) and NK cells, which produce anti-tumour cytokine IFN-γ that signals via STAT1 via 76 
JAK1/2 (8). In contrast, those cells shown to actively promote tumour growth include 77 
macrophages, innate lymphoid cells (ILC2s, ILC3s) and neutrophils. The equilibrium phase 78 
describes a state of dormancy or senescence between the tumour and host that is currently 79 
poorly understood (7). The escape phase is characterised by an immunosuppressive 80 
microenvironment, which allows the tumour to evade immunosurveillance and escape 81 
subsequent attack. For the purposes identifying potential therapeutic targets, this review will 82 
focus on detrimental effects of immune cells and their activation of signalling cascades that 83 
promote tumorigenesis.  84 
 85 
These tumour and immune/inflammatory responses whether at the intra-cellular, 86 
cellular or systemic levels appear to be similar across gastrointestinal tumour types and have 87 
prognostic value. Therefore, indicating the importance of such inflammatory phenotypes in 88 
gastrointestinal tumours.  The aim of the present review was to examine the relationships of 89 
inflammatory phenotypes at the intra-cellular, cellular and systemic levels in patients with 90 
gastrointestinal cancer and discuss the prospects for therapeutic intervention. 91 
 92 
1.1 Intracellular inflammatory phenotypes 93 
 There are a number of signal transduction pathways that may be considered to be 94 
important in tumour cell maintenance and characterisation of an intracellular inflammatory 95 
phenotype.  Historically, there is a great deal of both epidemiology and clinical evidence that 96 
the cyclooxygenase enzyme (COX), in particular COX2/ PGE2 pathway, plays a key role in 97 
the development and progression of intestinal cancers. Its activation results in many of the 98 
hallmarks of cancer and regulation of other signalling pathways (9, 10, 11). For example, up 99 
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regulation of COX-2 has been shown in the majority of gastrointestinal cancers and appears 100 
to promote WNT signalling, epithelial mesenchymal transition (EMT), angiogenesis, and 101 
resistance to chemotherapy induced apoptosis. Furthermore, the benefits of taking aspirin and 102 
other non-steroidal anti-inflammatory drugs (NSAIDs) that target this pathway on reducing 103 
the lifetime risk of gastrointestinal, especially colorectal, cancer have been well documented. 104 
As a consequence, many individuals with no evidence of disease now regularly take aspirin 105 
(12).  Although the basis of this protective effect is most probably by the regulation of 106 
immune/inflammatory responses at the intracellular, cellular and systemic levels, the 107 
molecular mechanism is not clear. 108 
In terms of the molecular mechanism, it is recognised that COX2 is a target gene of 109 
Nuclear Factor Kappa B (NF-κB) responsible for prostaglandin synthesis and that aspirin 110 
consumption induces phosphorylation and degradation of IKK-B, resulting in inhibition of 111 
NF-κB nuclear translocation and therefore a decrease in COX2 expression (13, 14).   There 112 
are 5 members of the NF-κB family: p65/RelA, p105/p50, RelB, p100/p52 and c-Rel.  These 113 
transcription factors are controlled by 2 signalling pathways termed the canonical and non-114 
canonical pathways (Figure 1). The canonical pathway is regulated by the IKK/IKK/IKK 115 
complex, which induces degradation of IκB, allowing p65 and p50 to dimerise and 116 
translocate to the nucleus to act as a transcription factor.   In contrast, the non-canonical 117 
pathway only involves IKK that acts with NIK to phosphorylate p100, inducing proteolysis 118 
and formation of p52, which dimerises with RelB and translocates to the nucleus where it 119 
also acts as a transcription factor.  120 
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 121 
Figure 1: Crosstalk of NF-κB Pathway in Colorectal Cancer  122 
The well-documented NF-κB canonical pathway can be initiated via TNFα binding its receptor, TNFR. This 123 
results in activation of the IκK complex causing IκBα phosphorylation and ubiquitination resulting in NF-κB 124 
translocating to the nucleus where it regulates gene transcription. The canonical or alternative pathway occurs 125 
via the lymphotoxin receptor activating IκKα, phosphorylation of p100 and translocation to the nucleus. COX2 126 
is a main target of NF-κB, and its induction results in blockade of AKT pathway, initiation of Wnt signalling 127 
and activation of STAT3. IL-6 and TNF-α are produced via STAT3 signalling. The crosstalk of NF-κB with 128 
other pathways ultimately leads to tumour cell proliferation and invasion. 129 
 130 
 131 
NF-κB signalling pathways are well established as promoting tumour growth and 132 
progression as well as controlling immune responses. Activation of the NF-κB pathway in 133 
tumour and stromal cells results in secretion of factors into the tumour microenvironment that 134 
co-ordinate innate and adaptive immune responses, induce angiogenesis, and promote tumour 135 
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cell proliferation and invasion. Therefore, NF-κB is not only activated in response to 136 
inflammatory stimuli but also regulates the inflammatory response. It also enables the tumour 137 
cells to be pro-proliferative via inducing expression of many genes involved in many other 138 
cellular processes eg: Cyclin D1 in cell cycle and proliferation; Bcl-CL anti-apoptosis; VEGF 139 
regulation of angiogenesis; MMP-9 regulation of invasion and increased secretion of growth 140 
factors and cytokines.  141 
In particular, it would appear that an activated canonical NF-κB pathway in colorectal 142 
tumours is associated with poor outcome.  For example, increased expression of NF-κB/RelA 143 
has been shown to be activated in colorectal carcinoma tissues (15). Sakomoto et al observed 144 
activation of NF-κB in 40% of colorectal cancer tissues and 67% of cell lines.  Higher levels 145 
of NF-κB activation in human colorectal carcinoma tissue have been correlated with tumour 146 
progression and a higher T-stage (16). More specifically activation may contribute to tumour 147 
angiogenesis in colorectal cancer (15). Expression of the p65 subunit is up-regulated at the 148 
invasive margin and in the mucinous tumour cells in colorectal cancer (17) and it is been 149 
widely reported that p65 expression is up-regulated in colorectal tumour tissue compared to 150 
matched normal, and that its expression increases in response to intervention and is 151 
associated with poor prognosis, particularly in rectal cancer (18, 19).   152 
The prognostic power of p65 can be increased by measuring the activated form NF-κB 153 
phosphorylated at Serine 536 and also by looking at cellular locations.  Lewander and co-154 
workers (2012) reported that, in a cohort of 203 patients with colorectal cancer, that phospho-155 
p65 expression was associated with shorter patient survival (20).  We have recently observed 156 
that IKK expression (the catalytic component of the canonical NF-κB pathway) was 157 
associated with the tumour microenvironment and local inflammatory infiltrate and this was 158 
associated with cancer specific survival (Edwards et al. unpublished results).  In addition, 159 
when patients were stratified by BRAF status, the association between cytoplasmic IKKand 160 
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cancer specific survival was upheld in patients with wild type BRAF but negated in those 161 
with mutated BRAF, suggesting this could be a possible target for those patients not 162 
responding to chemotherapy or EGFR and BRAF inhibitors.    163 
There is less evidence in the literature that the non-canonical pathway is involved in 164 
colorectal cancer, and the main focus is on the role of IKKα (the catalytic component of the 165 
non-canonical pathway) which is involved in both the canonical and non-canonical pathways. 166 
Perhaps a better marker for the activation of the non-canonical pathway would be RelB which 167 
dimerises with p52 to form the transcription factor. However, few studies have investigated 168 
the role of RelB with regards to patient outcome measures. We have observed that high RelB 169 
expression was associated with local inflammatory infiltrate, tumour stroma percentage and 170 
shorter cancer specific survival but not associated with the systemic inflammatory response in 171 
right sided colon tumours and rectal tumours.   We have in our group observed that elevated 172 
IKK is associated with reduced cancer specific survival in a cohort of 700 patients.   173 
  174 
More recently, there is evidence that COX2/ PGE2 mediates the activation of the 175 
JAK/STAT pathway, in particular STAT3 (21). Furthermore, upregulation of COX2 may 176 
promote tumour dissemination through activation of both NF-κB and STAT3 in tumour-177 
associated fibroblasts rather than in the tumour cells (Figure 1).  In turn, it has been shown 178 
that tumour-associated fibroblasts and other stromal cells have elevated expression of COX2, 179 
NF-κB and STAT3 which stimulates increased secretion of IL-6 and TNFα to promote 180 
tumour cell proliferation.   181 
The signal transducer and activator of transcription (STAT) pathways are of particular 182 
interest since they are primarily under the control of the janus kinases (JAK1, JAK2 and 183 
JAK3) and these are required for immune cell activation and have been therapeutically 184 
targeted in various myeloproliferative disorders.  JAKs phosphorylate STATs to transmit 185 
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information from the membrane to the cell nucleus, where STATs act as transcription factors 186 
to regulate many cytoprotective genes including anti-apoptotic genes such as MCL-1, BCL-187 
XL, BCL-2, survivin, HSP90 and HSP70; proliferation regulatory genes such as cyclin D1, 188 
cyclin B, c-jun, and c-Fos and angiogenesis promoting genes such as HIF1α and growth 189 
factors such as Il-6, FGF, EGF, and VEGF (22, 23).  190 
In mammalian cells there are seven members of the STAT protein family.  STAT1, 191 
STAT3, STAT4 and STAT5 are the family members most commonly reported to be 192 
expressed in gastrointestinal cancers. (24, 25, 26).  Cytokines and growth factors are the main 193 
ligands responsible for activating the STAT family members, however they may also be 194 
activated intrinsically via amplification of HER2, up-regulation of Src kinase or silencing of 195 
SOC3.  196 
Activation of STATs via receptors and kinases results in phosphorylation allowing 197 
them to form homo/heterodimers and translocate to the nucleus where they act as 198 
transcription factors.  Classically STAT1 has been associated with tumour suppression and 199 
STAT3 with oncogenesis, however both have been reported to have tumour promoting and 200 
tumour suppressive roles.  For example, activation of STAT3 can result in activation of the 201 
MMPs that can promote tumour cell invasion and interactions with other tumour promoting 202 
pathways such as NF-κB and COX2.  In general, persistent activation of these pathways in 203 
tumour cells and microenvironment results in the accumulation of stroma around the tumour 204 
cells and the loss of anti-tumour T-lymphocyte responses.   205 
Taken together this emphasises the importance of the cross talk between the above 206 
signalling pathways and different cells in the tumour microenvironment to inhibit or promote 207 
tumour cell proliferation and invasion. Recently, it has been observed that there is further 208 
cross talk between COX2/PGE2 and the PTEN/Akt pathways (27).  An increased in 209 
expression of COX2 was observed to dampen the action of the PTEN/Akt pathway and it was 210 
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only in the absence of COX-2 expression, that increased activation of PTEN/Akt was 211 
associated with poorer prognosis (28).  Therefore, it would appear that intracellular crosstalk 212 
between COX-2, NF-κB, STAT3, and probably other pathways is critical to the behaviour of 213 
the tumour cells and their microenvironment in patients with gastrointestinal cancer.  214 
 215 
1.2 Cellular inflammatory phenotypes 216 
There are a number of immune cells that can be considered to be important in 217 
characterising an inflammatory cell phenotype.  In gastrointestinal cancers, neutrophils and 218 
macrophages (50:50) account for approximately 40% of inflammatory cells (29, 30) with 219 
lymphocytes mainly constituting the remaining 60%.  In contrast, lymphocytes only 220 
constitute approximately 30% of the circulating inflammatory immune cells with 221 
macrophages and neutrophils (85:15) being in the majority (31).  Therefore, there appears to 222 
be a disproportionately higher numbers of lymphocytes in the tumour microenvironment. 223 
However, innate immune cells can influence the surrounding microenvironment to 224 
increase the amount of stromal tissue thus reducing the effectiveness of the adaptive immune 225 
system (32).  This would be consistent with the concept that the cytotoxic T lymphocytic 226 
infiltrate can be down-regulated and the immune competence of the host overridden by the 227 
presence of activated innate and humoral immune responses (33, 34, 35).  For example, in 228 
colorectal cancer, it is increasingly appreciated that as tumours invade there are changes in 229 
the tumour microenvironment facilitating adaptive immune cells to displace innate immune 230 
cells (36, 37).  231 
        Finally, there is accumulating evidence that innate immune cells such as neutrophils, 232 
monocytes/macrophages and myeloid derived suppressor cells promote the metastatic process 233 
(38, 39, 40).  Indeed, an increase or maintenance of neutrophils and a reduction of 234 
lymphocytes in the circulation are recognised prognostic features of cancer-associated 235 
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inflammation (39). The pathways through which inflammatory cells initiate their 236 
carcinogenic effects are complex and likely heterogeneous (Figure 2). In neutrophils, 237 
activation of NF-κB via toll like receptors in a MyD88-dependant manner may be of 238 
importance (Figure 2) (20). Several studies have demonstrated that TLR-4 expression is 239 
increased in CRC patients, indicating a potential route for increased NF-κB activation in 240 
these patients (22, 41). Prolonged TLR-4 expression causes T cells to switch from a Th1 241 
phenotype to a tumour-promoting regulatory phenotype (41). A second signalling pathway 242 
linked to neutrophils and CRC pathogenesis is the IL-6/JAK1/2/STAT3 (42). Tumour cells 243 
produce GM-CSF, which induces up-regulation of PD-L1 on tumour-infiltrating neutrophils 244 
via JAK-STAT3 (43). PD-L1 causes immunosuppression via inhibiting Th1 cells and causing 245 
cytotoxic T cell anergy (43, 44). In addition, IL-6 activated STAT3 can crosstalk with EGFR 246 
signalling to promote tumour progression (45, 46). 247 
 248 
Figure 2: A snapshot of inflammatory cell signalling in Colorectal Cancer 249 
Tumour infiltrating macrophages (TAMS, MΦ), innate lymphoid cells (ILC-3) and Neutrophils (NΦ) produce 250 
Il-10, Il-22 and Il-6 respectively, which result in induction of signal transducer and activator of transcription-3. 251 
TAMs also produce Il-1β, which causes upregulation of COX-2 and activation of the Wnt signalling pathway. 252 
ILC-2s are activated by Il-33 from epithelial cells to produce Il-13 which activates TAMs to take on a pro-253 
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tumour phenotype. The Il-33 can also act independently of ILC-2s to activate the NF-κβ cascade and promote 254 
tumorigenesis.  255 
 256 
          In addition to neutrophils, increased numbers of tumour-associated macrophages 257 
(TAMs) correlate with clinical factors such as tumour stage and lymph node metastasis (47). 258 
There is evidence that TAMs promote tumorigenesis, in part, through the production of the 259 
anti-inflammatory cytokine IL-10 (Figure 2). When bound to its receptor, IL-10 induces 260 
JAK-1 and TYK-2 activation, ultimately leading to STAT3 induction, which causes increased 261 
resistance of tumour cells to apoptosis (48). Sustained STAT3 signalling is associated with an 262 
increase in anti-apoptotic markers Bcl-x and Mcl-1 (48). In addition, increased STAT3 263 
expression is an indicator of poor prognosis and is associated with systemic inflammation 264 
(49). In CRC, another important function of TAMs is production of Il-1β, which induces up-265 
regulation of COX2 (50). This leads to phosphorylation of GSK- β, stabilization of β-catenin 266 
and induction of Wnt signalling to promote tumour progression (51).  267 
           In addition to traditional innate immune cells, a new subset of lymphoid-derived cells 268 
considered to function as part of the innate system, innate lymphoid cells (ILCs), have 269 
emerging roles in CRC (Figure 2). Innate lymphoid cell 3 (ILC-3) is a subset of ILCs 270 
abundant at mucosal sites where they play a role in maintenance of intestinal integrity. From 271 
a signalling perspective, a member of the IL-10 family of cytokines, IL-22, acts with 272 
interferons to induce iNOS production via STAT3, and the source of IL-22 is thought to be 273 
ILC-3s (52, 53). Dendritic cells in close proximity to the ILC3s produce IL-18, which 274 
induces the production of IL-22 (54). This occurs via NF-κB signalling, with p65 binding to 275 
the promoter region of IL-22 (54). Depletion of ILC-3s in murine models has been shown to 276 
reduce circulating levels of IL-22 and reduce the incidence of adenocarcinomas (55). 277 
Furthermore, iNOS expression associates with intratumour microvessel density and VEGF 278 
expression (56). Therefore ILC3s may be involved in angiogenesis and promotion of a pro-279 
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tumour microenvironment. Another subset of innate lymphoid cells, ILC2s, are also found at 280 
mucosal sites, however, their involvement in tumorigenesis is somewhat limited. They have 281 
been shown to cause TAMs to switch from an M1 to an M2 phenotype via IL-13 production 282 
(56, 57).  283 
Overall, it is clear that the innate immune system plays a critical role in the 284 
development and progression of CRC. However, the nature of this involvement is 285 
complicated, with neutrophils, TAMS, ILCs, dendritic cells, and stromal cells amongst others 286 
involved in this orchestration of CRC tumorigenesis. It is still not clear if innate and 287 
lymphoid cells represent different points in immune cell evolution of fighting the tumour or if 288 
they represent a different type of carcinogenesis/tumour progression.  However with the 289 
evidence emerging on checkpoint exhaustion and gamma delta T cells bridging the changes 290 
from adaptive to innate immune responses the evidence is weighted toward the first 291 
hypothesis, but additional evidence is required before this can be confirmed. 292 
 293 
1.3 Systemic inflammatory phenotypes 294 
It has long been recognised that humoral responses are activated in patients with 295 
gastrointestinal cancers (58).  It is only in the last 15 years the significance of this response 296 
and in particular the prognostic value of mediators of the systemic inflammatory phenotypes 297 
have been widely recognised.  A large number of components of this humoral response have 298 
now been identified and include counter-regulatory hormones, complement, collectins, 299 
ficolins, pentraxins, cytokines, adipokines and chemokines.  In the presence of cancer these 300 
mediators of the systemic inflammatory response are known to have complex interactions 301 
that are potentially detrimental to the host. There is also good evidence that IL-6 is directly 302 
associated with C-reactive protein (CRP) (59, 60) and is increasingly recognised to have 303 
independent prognostic value (61). Furthermore, CRP and its combination with albumin 304 
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(GPS/mGPS) is now widely recognised to have independent prognostic value in patients with 305 
gastrointestinal cancer (62, 63). 306 
The composition of immune cells within the circulation can also be of prognostic 307 
value., For example, the neutrophil to lymphocyte ratio (NLR) is independently prognostic 308 
and neutrophilia is strongly associated with poorer outcomes (64). NLRs prognostic ability is 309 
likely related to factors such as leptin, PrTH, albumin and CRP, which lead to cachexia, pain 310 
and reduced metabolism of drugs (64). Furthermore high NLR is associated with metastasis 311 
and increased NF-κB and STAT3 signalling within the tumour (64, 65, 66)  312 
Circulating IL-6 may provide another link between systemic inflammation and 313 
tumorigenesis (Figure 3). The main source of elevated IL-6 within the tumour is cancer-314 
associated fibroblasts (CAFs) (67). IL-6 acts to promote tumour growth via phosphorylation 315 
of gp130 on STAT3, causing translocation to the nucleus of the tumour cell, where STAT3 316 
acts as a transcription factor to promote a tumorigenic environment and angiogenesis (67, 68) 317 
Cytoplasmic STAT3 within tumour cells has been shown to correlate with mGPS and 318 
reduced survival (68).  319 
 320 
 321 
  
 15 
 322 
 323 
Figure 3: Broad role of the Il-6/JAK/STAT3 Pathway in Colorectal Cancer  324 
Chronic Il-6/JAK/STAT3 signalling is an important aspect of both the local and systemic immune responses in 325 
colorectal cancer. Activation of the pathway in both adaptive and innate cells can cause complement induction, 326 
production of opsonins and antibodies. Within the tumour necrosis causes activation of surrounding stromal 327 
tissue such as epithelial cells and myocytes which results in production of IL-10, IL-6 VEGF and interferons. 328 
The Il-6/JAK/STAT3 can promote elimination or progression of the tumour.     329 
 330 
Another link between systemic inflammation and the tumour microenvironment is the 331 
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strong association between mGPS and both FoxP3+ regulatory T cells and CD1a positive 332 
dendritic cells within the tumour (69).  Serum levels of cytokines and chemokines such as IL-333 
12 and CCL4 also associate with intra-tumour changes. Increased systemic IL-12 correlates 334 
with an overall increase of CD3+ T lymphocytes, in particular CD8+ cytotoxic T cells, and 335 
increased neutrophils (69). Whereas, elevated systemic CCL4 correlates with increased 336 
CD68+ macrophages at the invasive margin of the tumour (69). Although the translational 337 
potential of such associations is currently unclear, this highlights a strong link between 338 
systemic inflammatory phenotypes and cellular inflammatory phenotypes. Furthermore, the 339 
systemic changes associated with tumour progression may provide us with a tool to easily 340 
and non-invasively predict patient prognosis. 341 
 342 
1.4 Therapeutic intervention for inflammatory phenotypes 343 
From the above it is clear that there is potential for the modification of inflammatory 344 
phenotypes at the intracellular, cellular and the systemic levels.  Furthermore, there are 345 
networks that appear central to these inflammatory phenotypes at all levels.  In particular, the 346 
modification of the COX2/ PGE2 pathway has been extensively investigated in-vitro and in-347 
vivo and NSAIDs moderating this pathway have been shown to have clinical efficacy.  348 
Likewise, the IL-6/JAK/STAT3 pathway can activate the JAK/STAT pathway in 349 
inflammatory and stromal cells to modulate the tumour microenvironment and effect 350 
systemic level responses.  Indeed, this pathway is central to the regulation of innate 351 
immune/inflammatory responses (65, 70) as it is recognised to stimulate neutrophils and 352 
macrophage production from myeloid tissue and CRP secretion from hepatocytes (65).  353 
Inhibitors for this pathway are now emerging and present an interesting therapeutic for 354 
gastrointestinal tumours. 355 
Much of the above information describes associations of inflammatory phenotypes 356 
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and outcome in patients with cancer.  However, this may not be a cause and effect 357 
relationship. Indeed, a rational conclusion from the present review is that it would be 358 
important to explore the moderation of the intracellular, cellular and systemic inflammatory 359 
phenotypes.  With this perspective it may be concluded that much of current clinical 360 
management of gastrointestinal cancer needs to utilise a variety of approaches to moderate 361 
such inflammatory phenotypes whether it be by minimising the tissue injury associated with 362 
surgery, radiotherapy and chemotherapy treatments or the concurrent use of anti-363 
inflammatory agents.  For example, surgery is the primary treatment modality for many 364 
gastrointestinal cancers including CRC and its magnitude is likely to exacerbate 365 
immune/inflammatory phenotypes.  In such an acute injury, circulating IL-6, neutrophils and 366 
CRP show quantitatively the most significant increases (66) and these are recognised to be 367 
important in tissue repair and remodelling. Furthermore, activated granulocytes can produce 368 
growth factors (EGF, TGFβ, VEGF, Il-6, TNFα and chemokines) that can act directly on 369 
cancer cells and confer mitogenic and angiogenic capabilities (3, 71). 370 
However, to date, moderation of such inflammatory phenotypes have been carried out 371 
empirically (eg. laparoscopic/robotic approaches to speed up recovery from surgery) and not 372 
by specifically targeting inflammatory phenotypes.  Therefore, there is a need to examine 373 
what approaches may be useful to moderate intracellular, cellular and systemic inflammatory 374 
phenotypes.  These will encompass pharmacological approaches that may be classified 375 
according to those already established in clinical practice and those with novel therapeutic 376 
benefit.  377 
 378 
Established anti-inflammatory agents 379 
NSAIDs 380 
 NSAIDs have long been recognized to be useful in prevention and treatment of 381 
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patients with gastrointestinal cancer (72). Aspirin and other NSAIDs are effective in inducing 382 
apoptosis in tumour cells through COX2 and COX2-independent mechanisms.  Furthermore, 383 
the down regulation of the IL-6/ JAK/ STAT3 pathway has repeatedly been shown to be 384 
important in such apoptosis (Figure 4) (73). Moreover, NSAIDs appear to be effective in 385 
enhancing various aspects of anti-tumour immunity and immunotherapy (74). This would 386 
again indicate the pre-eminence of the COX2/PGE2 and IL-6/JAK/STAT pathways as well as 387 
related cytokines and growth factors on gastrointestinal cancer outcomes.  Furthermore, if 388 
efficacy for suppressing the IL-6/JAK/STAT pathway was also proven their use would 389 
further increase in clinical oncological practice. 390 
 391 
Figure 4: Targeted Therapy in Colorectal Cancer  392 
There are a number of therapeutics, some established and some novel, which target signalling pathways 393 
associated with colorectal cancer. COX2-PGE2 is a major target of non-steroidal anti-inflammatory drugs 394 
(NSAIDs), glucocorticoids, curcumin and Berberine. Other than Berberine, these drugs also target aspects of 395 
NF-κB, which is also targeted by statins. Upregulation of bone morphogenic signalling and blockade of Il-6 396 
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represent two other functions of statins. Berberine additionally targets β-catenin, MMP9 and Stat3. NT157, 397 
small molecule inhibitors and monoclonal antibodies can target the Il-6/JAK/STAT pathway. NT157 can also 398 
inhibit IGF-1. The vast network of signalling pathway dysregulation associated with CRC makes for a variety of 399 
targets and a complex task. 400 
 401 
Glucocorticoids  402 
Glucocorticoids have long been recognized to have benefit in the treatment of cancer-403 
associated symptoms. They are known to also down regulate COX2/PGE2 and IL-404 
6/JAK/STAT pathways as well as related cytokines and growth factors, They further decrease 405 
production and activity of neutrophils and macrophages as well as reduce complement and 406 
pentraxin synthesis (Figure 4) (75, 76). Glucocorticoids interact with specific intracellular 407 
receptors in target tissues to alter the expression of corticosteroid-responsive genes.  408 
Specifically, glucocorticoid-specific receptors in the cell cytoplasm bind with steroid ligands 409 
to form hormone-receptor complexes that eventually translocate to the cell nucleus. There, 410 
these complexes bind to specific DNA sequences and alter their expression.  411 
Cell line work has demonstrated that glucocorticoids such as dexamethasone may 412 
prove useful in reducing tumour cell growth, increasing apoptosis and sensitivity to 413 
chemotherapy (77). The actions of dexamethasone may involve NF-κB signalling, as p65 414 
correlates with the alpha portion of the glucocorticoid receptor in CRC cell lines (Figure 4) 415 
(77). 416 
 417 
Statins 418 
 It has recently become apparent that statins, in addition to their lipid lowering effect, 419 
also have effects on inflammatory phenotypes (78; 79).  Statins have also been shown to have 420 
anti-tumour and anti-inflammatory activity in the AOM-DSS colon carcinogenesis mouse 421 
model (80).  As such there has been increasing interest in their use in patients with CRC.  422 
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Furthermore, there is evidence that simvastatin can exert anti-tumor effects by suppressing 423 
IL-6-induced phosphorylation of JAK2 and STAT3 (Figure 4) (81). One other pathway 424 
thought to be involved in statins ability to block tumour growth is the bone morphogenic 425 
pathway (BMP) (Figure 4). BMP2 is silenced by promoter hypermethylation in many gastric 426 
cancers including CRC, and statins can release BMP-2 from this silencing and induce 427 
downstream signaling (82). Moreover, naturally derived stains such as simvastatin have also 428 
been shown to have an inhibitory effect on NF-κB signalling (83). However, further study is 429 
still required to determine if statins show efficacy in suppressing the detrimental 430 
inflammatory phenotypes, and establishing through which signaling pathways they exert their 431 
effects. However, with their well-established safety profile, they could be readily 432 
incorporated into clinical oncology practice. 433 
Novel anti-inflammatory agents 434 
COX-2 and NF-κB  435 
Oral supplementation with curcumin, a component of the curry spice, has been 436 
implicated as a potential anti-cancer therapeutic option in many cancers (Figure 4) (84, 85). 437 
During a phase 1 clinical trial, in a patient cohort unresponsive to traditional chemotherapy, 438 
daily administration of curcumin reduced plasma levels of PGE2 (86). As up-regulation of the 439 
COX-2 gene is observed in CRC and results in overproduction of PGE2 (87) this suggests the 440 
mechanism through which curcumin exerts its anti-cancer is via the COX2 gene (86, 87, 88, 441 
89). In a similar study, curcumin has also been shown to decrease plasma TNF-α and increase 442 
expression of intra-tumour p53 to promote apoptosis (90).  443 
In addition to the well-established anti-cancer action of Aspirin, several other 444 
NSAIDs have been investigated for their efficacy in treating CRC. In a recent phase 1b 445 
clinical trial, COX-2 inhibitor Naproxen given at a dose of 440mg for 6 months decreased 446 
CRC-associated inflammation in patients with Lynch Syndrome (91). However in contrast, 447 
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treating patients with selective COX-2 inhibitor, celecoxib, in addition to current 448 
chemotherapy (Irinotecan, 5-Fluorouracil, and Leucovorin) in a phase II clinical trial, showed 449 
no increased efficacy in stage IV patients (92). 450 
As well as its effects on the COX2/PGE2 and IL6/JAK/STAT3 pathways, Aspirin has 451 
been shown to inhibit a component of the NF-κB pathway, IKK-β (Figure 4). In the absence 452 
of IKK-β, phosphorylation of IKB is reduced, rendering NF-κB unable to carry out its 453 
function as a transcription factor (14). Inhibiting IKKs directly has repeatedly shown promise 454 
in depleting cancer in vitro and in vivo. Drugs targeting IKKs specifically, as opposed to 455 
broad anti-inflammatory agents are a huge focus in current CRC research (93). 456 
One alternative to NSAIDs, shown to have potential as an anti-CRC agent via COX2 457 
signalling is Berberine, a plant-derived isoquinoline (Figure 4). It acts via blockade of β-458 
catenin, thereby inhibiting Wnt signalling, and reducing COX2/PGE, JAK2 and STAT3 (19, 459 
95). In CRC cell lines, Berberine reduces MMP9 expression and prevents metastasis (21). A 460 
clinical trial investigating the role of Berberine as a recurrence prevention method began in 461 
2017 and will provide valuable insight into Berberine’s efficacy and safety in CRC patients.  462 
Another novel therapeutic is NT157, which targets both insulin growth factor 1 (IGF-463 
1) and STAT3 simultaneously (Figure 4). In murine models of CRC, dual blockade of IGF-1 464 
and STAT3 using NT157 results in inhibition of IL-6, Il-11, Il-23, CCL-2, CCL-5 and TGF-β 465 
as well as tumour cell migration (95). NT157 represents a promising anti-cancer agent; 466 
however its effects are still to be determined in humans. 467 
 468 
IL-6/JAK/ STAT blockade 469 
There is increasing interest in the selective down regulation of the components of this 470 
pathway in a variety of common cancers (96, 97).  In particular, the inhibition of the 471 
production of CRP, measured by a fall in circulating concentrations, has proven to be reliable 472 
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surrogate marker of anti-IL6 therapy efficacy. IL-6 blockade is thought to produce a profound 473 
reduction in systemic inflammatory phenotypes such as anorexia and cachexia (98). There are 474 
two clinically registered drugs siltuximab (99) and tocilizumab (100) that have been shown to 475 
have moderating effects on systemic inflammatory phenotypes (Figure 4). 476 
As in other ubiquitous signalling cascades, activation of the JAK/STAT pathway is tightly 477 
controlled at multiple levels with influence from other signalling cascades. Nevertheless, it is 478 
clear that the JAK/STAT pathway is activated in a variety of solid tumours contributing to an 479 
aggressive inflammatory phenotype. In particular, this pathway would appear to have a global 480 
role in adaptation of cancer cells to a hypoxic environment (101).   Therefore, it makes an 481 
attractive therapeutic target in patients with cancer and is currently the subject of intense 482 
research.  To date, there are two clinically registered JAK1/JAK2 inhibitors, Ruxolitinib and 483 
Pacritinib, and these are the subjects of on-going clinical trials in patients with cancer (Figure 484 
4).  The clinical utility of Ruxolitinib has been established in myelofibrois (a 485 
myeloproliferative neoplasm) in a series of landmark studies (102).  Furthermore, Hurwitz 486 
and co-authors (2014) recently reported the results, of a randomized double-blind phase 2 487 
study of ruxolitinib or placebo with capecitabine as second-line therapy in patients with 488 
metastatic pancreatic cancer (103). They showed that the combination was associated with 489 
improved survival particularly in those patients with an elevated circulating CRP 490 
concentration (103). There are now a number of randomised clinical trials of Ruxolitinib 491 
ongoing in variety of solid tumours. In one particular phase 2 clinical trial, administration of 492 
Ruxolitinib in combination with anti-VEGF agent Regorafinib, in stage IV CRC patients 493 
showed no improvement to overall survival when compared to Regorafinib treatment alone 494 
(104). To date, the clinical use of Pacritinib has been reported exclusively in 495 
myeloproliferative neoplasms. In terms of CRC, one trial investigating the safety of Pacritinib 496 
in metastatic disease reported no benefit to patients and administration was stopped before 497 
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the study end-point (105). Finally, blockade of the inhibitory molecule PD-1 (Nivolumab, 498 
Pembrolizumab) expressed on numerous immune populations including Th1 cells has proven 499 
useful in treating non-small cell lung cancer and MSI-high CRC. However a large proportion 500 
of CRC patients do not respond to anti-PD-1 monotherapy which is surprising given the 501 
improved prognosis associated with an increased inflammatory infiltrate in CRC as defined 502 
by the Immunoscore (106, 107). The limited efficacy of anti-PD1 in CRC may be explained 503 
by the immune evasion stage of Immunoediting (108). One function of anti-PD1 is to 504 
increase the effector functions of T cells, but if the tumour cells develop mechanisms to 505 
evade the immune response then the T cells would be unable to recognise the tumour and 506 
exert these effector functions (108). Alternatively, due to the heterogeneity of pathogenesis 507 
observed in CRC, other routes to tumourogenesis may out-compete the actions of anti-PD1. 508 
The gut harbours a unique combination of different cell types, which may account for why 509 
PD-1 blockade is unsuccessful in most CRC cases but successful in other cancer types (non-510 
small cell lung cancer) (109). ILCs represent a cell population likely to account for a poor 511 
response rate to anti-PD1. They are abundant in the gut and can have pro-tumour functions 512 
such as the production of IL-10 (52). Despite the disappointing results of anti-PD1 in CRC so 513 
far, the use of Nivolumab and/or Pembrolizumab may still harbour benefits if used in 514 
combination with other therapies that can prime the immune response. 515 
 516 
Conclusion 517 
 Targeting the host intracellular, cellular and systemic inflammatory phenotypes has 518 
considerable potential to improve outcomes in patients with gastrointestinal cancer.  For such 519 
a strategy to work there is a need for a well-characterised network of intracellular, cellular 520 
and systemic inflammatory phenotypes.     521 
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